Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zanchi, Cristina ^a   Locatelli, Monica ^a   Benigni, Ariela ^a   Corna, Daniela ^a   Tomasoni, Susanna ^a   Rottoli, Daniela ^a   Gaspari, Flavio ^a   Remuzzi, Giuseppe ^a,b   Zoja, Carlamaria ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MESSENGER RNA; PHOSPHATE; RAMIPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; KIDNEY DISTAL TUBULE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOSPHATE BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT RESPONSE; ZUCKER DIABETIC FATTY RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCURONIDASE; KIDNEY; MALE; PEPTIDYL-DIPEPTIDASE A; PHOSPHATES; RATS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS;

EID: 84881535981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070775     Document Type: Article

References (36)

1. Wolf M, (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435.
2. Seiler S, Heine GH, Fliser D (2009) Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 114: S34-42.
3. Juppner H (2011) Phosphate and FGF-23. Kidney Int Suppl 121: S24-27.
4. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, et al. (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297: F282-291.
5. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 17: 1305-1315.
6. Kuro-o M, (2010) Overview of the FGF23-Klotho axis. Pediatr Nephrol 25: 583-590.
7. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774.
8. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, et al. (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40: 1565-1573.
9. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, et al. (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408.
10. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505.
11. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, et al. (2011) FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 6: 241-247.
12. Mirams M, Robinson BG, Mason RS, Nelson AE, (2004) Bone as a source of FGF23: regulation by phosphate? Bone 35: 1192-1199.
13. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, et al. (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426.
14. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, et al. (2009) Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 111: 61-68.
15. Schafer S, Linz W, Bube A, Gerl M, Huber J, et al. (2003) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60: 447-454.
16. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, et al. (2009) Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2384-2391.
17. Baylis C, Atzpodien EA, Freshour G, Engels K, (2003) Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307: 854-860.
18. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, et al. (2004) Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 13: 11-19.
19. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, et al. (2011) Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 301: F1114-1123.
20. Tang WJ, Wang LF, Xu XY, Zhou Y, Jin WF, et al. (2010) Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif Tissue Int 86: 404-410.
21. Forster IC, Hernando N, Biber J, Murer H, (2006) Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 70: 1548-1559.
22. Kuro-o M, (2012) Klotho in health and disease. Curr Opin Nephrol Hypertens 21: 362-368.
23. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, et al. (2010) Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24: 3438-3450.
24. Farrow EG, Davis SI, Summers LJ, White KE, (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20: 955-960.
25. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, et al. (2001) Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015-1020.
26. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51.
27. Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, et al. (2011) Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 60: 1907-1916.
28. Sugiura H, Yoshida T, Shiohira S, Kohei J, Mitobe M, et al. (2012) Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol 302: F1252-1264.
29. de Borst MH, Vervloet MG, ter Wee PM, Navis G, (2011) Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 22: 1603-1609.
30. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, et al. (2002) In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39: 838-843.
31. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, et al. (2011) Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 26: 800-813.
32. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, et al. (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685.
33. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552.
34. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, et al. (2012) Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162.
35. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, et al. (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122: 2543-2553.
36. Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, et al. (2012) Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol 13: 20.